News — Herpes RSS

RIDER Institute Q&A

DRACO Q&A – the following Questions (Q:) were asked by several of you who completed the provided form. All answers following the “A:” were written by Dr.Rider. Q: Judging by the slow pace of FDA drug approval, is there a way to get a more blanket-like approval for concurrent trials of the DRACO method for different diseases? A: That is a very interesting idea, but before we can get to questions about FDA approval, we need to test and optimize DRACOs against major clinically relevant viruses in cells and in animal experiments. Q: First of all, thanks for your passion and hard work to help make the world a better place to live. I would like to know if DRACOs can address infections of...

Continue reading

Testing and Optimizing DRACO Therapeutics Against Members of the Herpesvirus Family

April 12, 2016 BACKGROUND AND MOTIVATION Currently there are relatively few prophylactics or therapeutics for viruses, and most that do exist are highly pathogen-specific or have undesirable side effects or other disadvantages. We have developed a radically new, broad-spectrum antiviral therapeutic/prophylactic that has the potential to revolutionize the treatment of viral infections. Our Double-stranded RNA Activated Caspase Oligomerizer (DRACO) approach selectively induces apoptosis (cell suicide) in cells containing viral double-stranded RNA (dsRNA). DRACO should recognize virus-infected cells and rapidly kill those cells without harming uninfected cells, thereby terminating the viral infection while minimizing the impact on the host (PLoS ONE 6:e22572, 2011; Nature Biotechnology 29:885, 2011; U.S. patents 7,125,839, 7,566,694, and others pending). We have previously created an initial version...

Continue reading